Welcome to our dedicated page for Liquidia news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia stock.
Liquidia Corporation develops and commercializes therapies for respiratory and vascular diseases, with a focus on pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its updates center on YUTREPIA® (treprostinil) inhalation powder, the company’s PRINT® Technology-enabled approved therapy, along with L606, an investigational extended-release treprostinil formulation administered with a nebulizer, and generic Treprostinil Injection for PAH.
Recurring news includes financial results, YUTREPIA commercial uptake, clinical data presentations, pipeline studies, corporate presentations and investor conference participation. Company updates also discuss treprostinil delivery, PAH and PH-ILD treatment settings, cash generation and profitability as product sales become a larger part of Liquidia’s operating profile.
Liquidia (NASDAQ:LQDA) will present four posters at the PHA 2026 International PH Conference and Scientific Sessions in Dallas, June 11-14, 2026.
Posters cover ASCENT study data on YUTREPIA in PH-ILD, patient-reported cough, caregiver mental health, pharmacist roles, and an encore of safety and exploratory efficacy data.
Liquidia (Nasdaq:LQDA) announced its inclusion in the S&P SmallCap 600 Index, effective before market open on June 22, 2026. The index tracks 600 U.S. small-cap companies chosen by S&P Dow Jones Indices using market cap, liquidity, public float, and profitability criteria.
Liquidia (Nasdaq:LQDA) announced that CEO Dr. Roger Jeffs and COO/CFO Michael Kaseta will discuss the company’s business in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 3, 2026 at 12:45 p.m. ET. The live webcast and a 30-day replay will be available on the company’s investor relations website.
Liquidia (NASDAQ:LQDA) reported strong first quarter 2026 results driven by YUTREPIA inhalation powder. Product sales, net, reached $129.9 million, supporting net income of $52.9 million and adjusted EBITDA of $71.2 million. Cash and cash equivalents rose to $222.8 million.
Since YUTREPIA’s June 2025 launch, more than 4,500 unique prescriptions were received and about 3,750 patients started treatment, with conversion at or above 85%. Liquidia is also screening PH-ILD patients in Phase 4 Tyvaso/Tyvaso DPI transition and pivotal Phase 3 Re-Spire (L606) studies.
Liquidia (NASDAQ: LQDA) will participate in two investor conferences in May 2026 with senior management presenting company updates.
Executives Michael Kaseta and Jason Adair will hold fireside chats and one-on-one meetings at BofA Securities Health Care Conference (May 13, 8:40 am PT, Las Vegas) and H.C. Wainwright Bioconnect at NASDAQ (May 19, 9:30 am ET, New York). Webcast access and replays are on the Investors page for at least 30 days.
Liquidia (Nasdaq: LQDA) will report first quarter 2026 financial results on Monday, May 11, 2026. The company will host a live webcast at 8:30 a.m. ET to discuss results and provide a corporate update.
The webcast will stream and be archived for one year at the company investor events page.
Liquidia (NASDAQ: LQDA) will participate in investor conferences on April 14–15, 2026, offering one-on-one meetings and a webcasted fireside chat.
Executives attending include CEO Dr. Roger Jeffs, COO/CFO Michael Kaseta, and Chief Business Officer Jason Adair. Webcast replay and transcript will be archived on the company Investors page for at least 30 days.
Liquidia (NASDAQ: LQDA) reported full year 2025 results with YUTREPIA product sales of $148.3 million and $90.1 million in Q4. The company recorded >3,600 unique prescriptions and 2,900 patients treated since the June 2025 launch.
Liquidia ended 2025 with $190.7 million cash, reported Q4 net income of $14.6 million and Q4 adjusted EBITDA of $27.3 million, but a full‑year net loss of $68.9 million. Management plans sales‑force growth, more clinical studies for YUTREPIA, and pivotal trials for L606 funded from operations.
Liquidia (Nasdaq: LQDA) will report full year 2025 financial results on March 5, 2026. A live webcast is scheduled for 8:30 a.m. Eastern Time to discuss results and provide a corporate update. A rebroadcast will be archived on the company website for one year.
Liquidia (NASDAQ: LQDA) will present three clinical posters at the Pulmonary Vascular Research Institute (PVRI) 2026 Annual Congress in Dublin, Ireland, Jan 28–Feb 1, 2026.
The presentations cover interim and open-label clinical data for inhaled treprostinil products: LIQ861 (YUTREPIA) in PH-ILD from the ASCENT study to Week 24, and 48-week open-label data for investigational L606 in PAH and PH-ILD. Specific sessions: Paper 83 on Jan 29 (3:45–5:00 p.m. GMT), Paper 166 on Jan 30 (3:10–4:15 p.m. GMT), and Paper 82 on Jan 31 (9:55–11:00 a.m. GMT). Posters will be posted on Liquidia’s publications webpage after the conference.